Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KHN707 in Chinese Healthy Volunteers
NCT07557537Phase 1Not yet recruiting
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
- Start
- May 2026
- Primary completion
- Oct 2026
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial comparing KHN707 tablets with Placebo (2 arms). Primary endpoint: Incidence and severity of adverse events at Day 4. Planned start May 2026; status: not yet recruiting.
02
Drugs
KHN707
Beyond the preview
Go deeper on NCT07557537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07557537.